# iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

Study · id `cardio:ct-nct05413369` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05413369](<https://clinicaltrials.gov/study/NCT05413369>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05413369

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 582 participants.

## Technical summary

Registry record NCT05413369. Randomized; no masking; primary purpose treatment. Start 2022-07-07 (actual); primary completion 2023-10-20 (actual). Results posted on 2024-10-30.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 582 participants (enrolled count; ClinicalTrials.gov record NCT05413369, source copy `cardio:ctgov-nct05413369-2025-09-24`, retrieved 2026-10-26)
- Started: 2022-07-07 (actual) (ClinicalTrials.gov record NCT05413369, source copy `cardio:ctgov-nct05413369-2025-09-24`, retrieved 2026-10-26)
- Primary completion: 2023-10-20 (actual) (ClinicalTrials.gov record NCT05413369, source copy `cardio:ctgov-nct05413369-2025-09-24`, retrieved 2026-10-26)
- Completion: 2023-10-20 (actual) (ClinicalTrials.gov record NCT05413369, source copy `cardio:ctgov-nct05413369-2025-09-24`, retrieved 2026-10-26)
- Results first posted: 2024-10-30 (ClinicalTrials.gov record NCT05413369, source copy `cardio:ctgov-nct05413369-2025-09-24`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05413369, source copy `cardio:ctgov-nct05413369-2025-09-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05413369-2025-09-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin glargine/Lixisenatide
- Intervention (Drug): IDegAsp
- Intervention (Drug): Metformin
- Intervention (Drug): SGLT2 inhibitor
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 3659f17a7d7e33f1a0d47a4ed0448dcdbb03a8d457ac837626ca024c1b9d748f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
